Ex vivo anti-malarial drugs sensitivity profile of Plasmodium falciparum field isolates from Burkina Faso five years after the national policy change
about
Multinormal in vitro distribution of Plasmodium falciparum susceptibility to piperaquine and pyronaridine.Drying anti-malarial drugs in vitro tests to outsource SYBR green assays.Impact of antimalarial treatment and chemoprevention on the drug sensitivity of malaria parasites isolated from ugandan children.Ex vivo anti-malarial drug susceptibility of Plasmodium falciparum isolates from pregnant women in an area of highly seasonal transmission in Burkina FasoArtesunate-Amodiaquine and Artemether-Lumefantrine Therapies and Selection of Pfcrt and Pfmdr1 Alleles in Nanoro, Burkina Faso.Effectiveness and safety of artemether-lumefantrine versus artesunate-amodiaquine for unsupervised treatment of uncomplicated falciparum malaria in patients of all age groups in Nanoro, Burkina Faso: a randomized open label trial.Dynamic of plasmodium falciparum chloroquine resistance transporter gene Pfcrt K76T mutation five years after withdrawal of chloroquine in Burkina Faso.Randomised controlled trial of two sequential artemisinin-based combination therapy regimens to treat uncomplicated falciparum malaria in African children: a protocol to investigate safety, efficacy and adherence.Multiple Phenotypic and Genotypic Artemisinin Sensitivity Evaluation of Malian Plasmodium falciparum Isolates.In vitro susceptibility of Indian Plasmodium falciparum isolates to different antimalarial drugs & antibiotics.A reference document on Permissible Limits for solvents and buffers during in vitro antimalarial screeningEmerging implications of policies on malaria treatment: genetic changes in the gene affecting susceptibility to artemether-lumefantrine and artesunate-amodiaquine in Africa
P2860
Q35068138-FFB1D281-DC2B-44FE-B2B1-9C6C13552491Q35116165-8D962CAB-F464-4A69-9FC7-66853A2D7CF9Q35607844-ACA45DA7-DF05-4544-8447-D0EDD9A9C28CQ35760573-E0916401-8724-45B2-9532-58CD5B4E4FFFQ35975011-0728EF84-1120-4202-8C6F-5785A92E29ADQ35986306-E8712812-B3DE-451C-8A62-E918C46F9BECQ36162404-D9A07132-247F-4806-9E7D-BCEA5A093084Q43923927-E43B3F26-CD09-4721-9A5D-DF1BE5E380E4Q50048811-95E479B8-E81B-4FAF-909A-3242A12B03B4Q52670155-3E8E6117-8FEB-4513-AFF5-257B5EFD74DEQ57296217-A2706FB1-C3CF-470B-8060-BE628AF15F7BQ58586501-03906FD7-CE90-4FAF-B556-5F70544F9783
P2860
Ex vivo anti-malarial drugs sensitivity profile of Plasmodium falciparum field isolates from Burkina Faso five years after the national policy change
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Ex vivo anti-malarial drugs se ...... ter the national policy change
@ast
Ex vivo anti-malarial drugs se ...... ter the national policy change
@en
type
label
Ex vivo anti-malarial drugs se ...... ter the national policy change
@ast
Ex vivo anti-malarial drugs se ...... ter the national policy change
@en
prefLabel
Ex vivo anti-malarial drugs se ...... ter the national policy change
@ast
Ex vivo anti-malarial drugs se ...... ter the national policy change
@en
P2093
P2860
P50
P921
P356
P1433
P1476
Ex vivo anti-malarial drugs se ...... ter the national policy change
@en
P2093
Adama Kazienga
Henk Schallig
Hermann Sorgho
Hervé Kpoda
Innocent Valéa
Isidore Yerbanga
Louis A Nana
Léa N Bonkian
Moussa Lingani
Petronella F Mens
P2860
P2888
P356
10.1186/1475-2875-13-207
P577
2014-05-31T00:00:00Z
P5875
P6179
1003896279